Compare Stocks → Guard Against the Coming Financial Upheaval (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVRONYSE:JATTNASDAQ:LENZNASDAQ:TCRR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$1.35+9.8%$1.26$0.57▼$1.70$55.22M1.24195,820 shs860,922 shsJATTJATT Acquisition$4.79+2.4%$3.57$7.80▼$12.38$82.63MN/A41,322 shs162,378 shsLENZLENZ Therapeutics$15.91+1.1%$0.00$14.07▼$29.82$57.40M0.33162,938 shs233,249 shsTCRRTCR2 Therapeutics$1.48-5.7%$1.65$0.82▼$3.88$58.11M1.95494,777 shs3.91 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO+9.76%+8.87%+6.30%+3.85%+112.20%JATTJATT Acquisition+2.35%+2.13%+42.56%+13.78%-20.70%LENZLENZ Therapeutics+1.14%-1.67%-27.32%+1,590,999,900.00%+1,590,999,900.00%TCRRTCR2 Therapeutics0.00%0.00%0.00%0.00%-24.49%What’s Really Next for America… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBIO2.3468 of 5 stars3.03.00.00.02.61.71.3JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ALENZLENZ Therapeutics4.14 of 5 stars4.50.00.00.02.84.21.3TCRRTCR2 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO2.00Hold$2.0048.15% UpsideJATTJATT AcquisitionN/AN/AN/AN/ALENZLENZ Therapeutics3.00Buy$31.3396.94% UpsideTCRRTCR2 TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest TCRR, LENZ, JATT, and AVRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/15/2024LENZLENZ TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform4/15/2024LENZLENZ TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$32.004/15/2024LENZLENZ TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/10/2024LENZLENZ TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$34.003/27/2024LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$28.00(Data available from 5/14/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/A$0.31 per share4.29$2.13 per shareN/AJATTJATT AcquisitionN/AN/A$0.18 per share27.08($0.53) per shareN/ALENZLENZ TherapeuticsN/AN/AN/AN/A$22.06 per shareN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/A$2.58 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16MN/A0.00N/AN/AN/A-50.52%-47.13%8/8/2024 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ALENZLENZ Therapeutics-$124.65MN/A0.00N/AN/AN/A-39.55%-33.40%8/12/2024 (Estimated)TCRRTCR2 Therapeutics-$151.82M-$4.20N/AN/AN/AN/A-97.81%-69.35%N/ALatest TCRR, LENZ, JATT, and AVRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2024Q1 2024AVROAVROBION/A-$0.15-$0.15-$0.15N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/ATCRRTCR2 TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A26.1726.17JATTJATT AcquisitionN/A0.150.15LENZLENZ TherapeuticsN/A11.4711.47TCRRTCR2 TherapeuticsN/A2.962.96OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%JATTJATT Acquisition47.97%LENZLENZ Therapeutics54.32%TCRRTCR2 Therapeutics64.76%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%JATTJATT Acquisition20.00%LENZLENZ Therapeutics38.40%TCRRTCR2 Therapeutics25.01%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.89 million40.76 millionOptionableJATTJATT Acquisition2,02117.25 million13.80 millionNot OptionableLENZLENZ TherapeuticsN/A3.65 million2.25 millionN/ATCRRTCR2 Therapeutics13739.26 million29.44 millionNot OptionableTCRR, LENZ, JATT, and AVRO HeadlinesRecent News About These CompaniesApril 17, 2024 | pharmaceutical-technology.comTCR2 Therapeutics gets grant for recombinant nucleic acid encoding TCR fusion protein for cancer treatmentFebruary 25, 2024 | morningstar.comPoseida Therapeutics Inc Ordinary Shares PSTXJune 20, 2023 | wsj.comDICE Therapeutics Inc.June 1, 2023 | finance.yahoo.comAdaptimmune Announces Completion of Strategic Combination with TCR2 Therapeutics Creating a Preeminent Solid Tumor Cell Therapy CompanyMay 16, 2023 | benzinga.comTCR2 Therapeutics Insider Trades Send a SignalMay 12, 2023 | msn.comRecap: TCR2 Therapeutics Q1 EarningsMay 11, 2023 | marketwatch.com10-Q: TCR2 THERAPEUTICS INC.May 11, 2023 | finance.yahoo.comTCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate UpdateApril 15, 2023 | finance.yahoo.comCompanies Like TCR2 Therapeutics (NASDAQ:TCRR) Could Be Quite RiskyMarch 25, 2023 | msn.comMizuho Downgrades Tcr2 Therapeutics (TCRR)March 23, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at Mizuho SecuritiesMarch 23, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TCR2 Therapeutics (TCRR) and Inozyme Pharma (INZY)March 23, 2023 | finanznachrichten.deTCR2 Therapeutics: TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 23, 2023 | finance.yahoo.comTCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate UpdateMarch 9, 2023 | msn.comWhat To Know About Jefferies's Downgrade of TCR2 TherapeuticsMarch 9, 2023 | markets.businessinsider.com4 Analysts Have This to Say About TCR2 TherapeuticsMarch 8, 2023 | markets.businessinsider.comTCR2 Therapeutics (TCRR) was downgraded to a Hold Rating at H.C. WainwrightMarch 6, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether TCR² Therapeutics Inc. has obtained a Fair Price in its transaction with AdaptimmuneMarch 6, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating TCR² Therapeutics Inc. BuyoutMarch 6, 2023 | investorplace.comWhy Is TCR2 Therapeutics (TCRR) Stock Up 30% Today?New MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.JATT AcquisitionNYSE:JATTJATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.LENZ TherapeuticsNASDAQ:LENZLENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.TCR2 TherapeuticsNASDAQ:TCRRTCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
